Kymera Therapeutics (KYMR) Short Interest Ratio & Short Volume $30.17 +0.04 (+0.13%) Closing price 04:00 PM EasternExtended Trading$29.30 -0.87 (-2.88%) As of 05:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Kymera Therapeutics Short Interest DataKymera Therapeutics (KYMR) has a short interest of 7.18 million shares. This marks a -2.58% decrease in short interest from the previous month. The short interest ratio (days to cover) is 9.8, indicating that it would take 9.8 days of the average trading volume of 562,333 shares to cover all short positions.Current Short Interest7,180,000 sharesPrevious Short Interest7,370,000 sharesChange Vs. Previous Month-2.58%Dollar Volume Sold Short$246.06 millionShort Interest Ratio9.8 Days to CoverLast Record DateApril 30, 2025Outstanding Shares65,120,000 sharesPercentage of Shares Shorted11.03%Today's Trading Volume386,402 sharesAverage Trading Volume562,333 sharesToday's Volume Vs. Average69% Short Selling Kymera Therapeutics? Sign up to receive the latest short interest report for Kymera Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartKYMR Short Interest Over TimeKYMR Days to Cover Over TimeKYMR Percentage of Float Shorted Over Time Kymera Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20257,180,000 shares $246.06 million -2.6%N/A9.8 $34.27 4/15/20257,370,000 shares $187.64 million -7.8%13.5%10.5 $25.46 3/31/20257,990,000 shares $218.69 million +1.9%14.7%12.2 $27.37 3/15/20257,840,000 shares $269.46 million +3.4%14.4%13.5 $34.37 2/28/20257,580,000 shares $237.63 million +3.3%13.9%13.6 $31.35 2/15/20257,340,000 shares $270.70 million -4.6%13.5%15 $36.88 1/31/20257,690,000 shares $304.45 million -7.9%N/A16 $39.59 1/15/20258,350,000 shares $363.73 million -4.8%N/A17.5 $43.56 12/31/20248,770,000 shares $352.82 million -0.2%N/A20.2 $40.23 12/15/20248,790,000 shares $370.32 million -2.6%N/A20.2 $42.13 Get the Latest News and Ratings for KYMR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/20249,020,000 shares $422.59 million -1.1%N/A20.8 $46.85 11/15/20249,120,000 shares $382.68 million -0.4%N/A21.9 $41.96 10/31/20249,160,000 shares $422.92 million +1.0%N/A22.2 $46.17 10/15/20249,070,000 shares $406.34 million +3.0%N/A21.4 $44.80 9/30/20248,810,000 shares $416.98 million -7.2%N/A17.5 $47.33 9/15/20249,490,000 shares $437.30 million +1.5%N/A16.8 $46.08 8/31/20249,350,000 shares $452.17 million -1.3%N/A16.2 $48.36 8/15/20249,470,000 shares $417.06 million -3.9%N/A15.6 $44.04 7/31/20249,850,000 shares $455.07 million -0.2%N/A16.1 $46.20 7/15/20249,870,000 shares $444.15 million +5.2%N/A16.1 $45.00 6/30/20249,380,000 shares $279.99 million -7.5%N/A16.4 $29.85 6/15/202410,140,000 shares $337.56 million +1.5%N/A19.6 $33.29 5/31/20249,990,000 shares $320.78 million +1.2%N/A17.6 $32.11 5/15/20249,870,000 shares $354.73 million -0.4%N/A16.9 $35.94 4/30/20249,910,000 shares $333.17 million +2.2%N/A16.2 $33.62 4/15/20249,700,000 shares $333.58 million +7.1%N/A14.8 $34.39 3/31/20249,060,000 shares $364.21 million +8.8%N/A12 $40.20 3/15/20248,330,000 shares $338.03 million +1.0%N/A10.2 $40.58 2/29/20248,250,000 shares $352.28 million -1.8%N/A9 $42.70 2/15/20248,400,000 shares $314.33 million +1.7%N/A9.4 $37.42 1/31/20248,260,000 shares $270.76 million -4.2%N/A8.9 $32.78 1/15/20248,620,000 shares $242.39 million -4.9%N/A9.3 $28.12 12/31/20239,060,000 shares $230.67 million +4.4%N/A9.4 $25.46 12/15/20238,680,000 shares $226.37 million +12.9%N/A9.9 $26.08 11/30/20237,690,000 shares $159.64 million +3.2%N/A10.3 $20.76 11/15/20237,450,000 shares $134.77 million -8.0%N/A11.2 $18.09 10/31/20238,100,000 shares $94.53 million +10.7%N/A13.9 $11.67 10/15/20237,320,000 shares $92.31 million +0.4%N/A14.2 $12.61 9/30/20237,290,000 shares $101.33 million -1.8%N/A17.9 $13.90 9/15/20237,420,000 shares $141.35 million +3.6%N/A19.7 $19.05Vladimir Lenin was right… (Ad)The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.Including the name of the #1 company to buy. 8/31/20237,160,000 shares $136.61 million -2.3%N/A17.1 $19.08 8/15/20237,330,000 shares $143.74 million -3.9%N/A15.5 $19.61 7/31/20237,630,000 shares $166.94 million -5.5%N/A15.3 $21.88 7/15/20238,070,000 shares $178.67 million -0.6%N/A15.5 $22.14 6/30/20238,120,000 shares $186.68 million -2.3%N/A15.2 $22.99 6/15/20238,310,000 shares $229.94 million -10.1%N/A15.5 $27.67 5/31/20239,240,000 shares $272.03 million -2.0%N/A18.8 $29.44 5/15/20239,430,000 shares $281.96 million -2.0%21.3%20.8 $29.90 4/30/20239,620,000 shares $303.41 million -0.2%21.7%21.4 $31.54 4/15/20239,640,000 shares $316.77 million +0.5%21.8%21.4 $32.86 3/31/20239,590,000 shares $284.15 million +2.0%21.7%18.6 $29.63 3/15/20239,400,000 shares $292.62 million -0.6%21.3%17.6 $31.13 2/28/20239,460,000 shares $296.85 million -0.7%21.4%13.2 $31.38 2/15/20239,530,000 shares $314.49 million -1.1%21.7%13.1 $33.00 1/31/20239,640,000 shares $360.34 million +2.4%21.9%12.9 $37.38 1/15/20239,410,000 shares $325.02 million +4.6%21.4%12.3 $34.54 12/30/20229,000,000 shares $224.64 million +11.8%20.5%11.7 $24.96 12/15/20228,050,000 shares $224.60 million +9.8%18.4%10.6 $27.90 11/30/20227,330,000 shares $212.42 million -7.0%16.9%11.7 $28.98 11/15/20227,880,000 shares $236.64 million -5.6%18.1%12.3 $30.03 10/31/20228,350,000 shares $253.34 million +8.4%19.3%12.6 $30.34 10/15/20227,700,000 shares $169.40 million +1.9%18.0%11.6 $22.00 9/30/20227,560,000 shares $164.58 million +10.2%17.9%11.7 $21.77 9/15/20226,860,000 shares $197.29 million +7.7%16.2%9.9 $28.76 8/31/20226,370,000 shares $180.08 million +7.4%15.1%8.9 $28.27 8/15/20225,930,000 shares $200.08 million -3.3%14.8%8.2 $33.74 7/31/20226,130,000 shares $135.04 million -4.1%15.3%8 $22.03 7/15/20226,390,000 shares $148.44 million +10.0%16.0%8 $23.23 6/30/20225,810,000 shares $114.40 million +16.9%14.5%7.5 $19.69 6/15/20224,970,000 shares $70.47 million +1.0%12.4%6.8 $14.18 5/31/20224,920,000 shares $70.21 million -0.2%12.3%7.6 $14.27 5/15/20224,930,000 shares $85.98 million +42.5%12.3%8.4 $17.44 4/30/20223,460,000 shares $108.47 million +6.1%8.7%6.8 $31.35 4/15/20223,260,000 shares $124.01 million +7.6%8.2%8 $38.04 3/31/20223,030,000 shares $128.23 million -3.5%7.6%7.4 $42.32 3/15/20223,140,000 shares $111.97 million +11.4%9.4%8 $35.66 2/28/20222,820,000 shares $112.12 million +8.1%8.4%7.2 $39.76 2/15/20222,610,000 shares $114.14 million +13.5%7.8%6.8 $43.73 1/31/20222,300,000 shares $96.60 million +12.2%7.5%6.4 $42.00 1/15/20222,050,000 shares $84.19 million +3.5%6.0%6.1 $41.07 12/31/20211,980,000 shares $125.71 million +17.2%5.8%7 $63.49 12/15/20211,690,000 shares $93.71 million -0.6%4.9%5.9 $55.45 11/30/20211,700,000 shares $94.38 million +13.3%5.0%5.6 $55.52 11/15/20211,500,000 shares $91.95 million +4.9%4.4%4.9 $61.30 10/29/20211,430,000 shares $84.20 million +0.7%4.4%4.4 $58.88 10/15/20211,420,000 shares $81.22 million -13.9%4.3%4.3 $57.20 9/30/20211,650,000 shares $96.92 million +8.6%5.0%4.5 $58.74 9/15/20211,520,000 shares $98.78 million -10.1%4.6%3.1 $64.99 8/31/20211,690,000 shares $105.02 million -15.5%5.1%3.5 $62.14 8/13/20212,000,000 shares $107.88 million -2.9%6.2%4.2 $53.94Trump Exec Order 14179 is wealth “gift” to good Americans? (Ad)Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.If you missed out on a bitcoin fortune, this could be your second chance. A brief “wealth window” is 7/30/20212,060,000 shares $123.97 million +5.6%7.1%4.2 $60.18 7/15/20211,950,000 shares $93.83 million -17.4%6.7%4 $48.12 6/30/20212,360,000 shares $114.46 million +30.4%8.1%4.8 $48.50 6/15/20211,810,000 shares $88.40 million -7.7%6.9%4.7 $48.84 5/28/20211,960,000 shares $94.26 million -8.8%7.4%4.5 $48.09 5/14/20212,150,000 shares $97.55 million -9.3%8.2%5 $45.37 4/30/20212,370,000 shares $108.31 million +3.0%9.6%6 $45.70 4/15/20212,300,000 shares $83.47 million +6.5%9.4%6.4 $36.29 3/31/20212,160,000 shares $78.68 million +100.0%8.9%6.7 $36.43 3/15/20211,080,000 shares $60.59 million +3.9%4.4%3.6 $56.10 2/26/20211,040,000 shares $51.58 million -13.3%4.3%4.9 $49.60 2/12/20211,200,000 shares $82.88 million +0.8%5.2%6.5 $69.07 1/29/20211,190,000 shares $76.01 million +8.2%5.2%6.9 $63.87 1/15/20211,100,000 shares $89.43 million No Change4.8%6.7 $81.30 KYMR Short Interest - Frequently Asked Questions What is Kymera Therapeutics' current short interest? Short interest is the volume of Kymera Therapeutics shares that have been sold short but have not yet been closed out or covered. As of April 30th, investors have sold 7,180,000 shares of KYMR short. Learn More on Kymera Therapeutics' current short interest. What is a good short interest ratio for Kymera Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. KYMR shares currently have a short interest ratio of 10.0. Learn More on Kymera Therapeutics's short interest ratio. Is Kymera Therapeutics' short interest increasing or decreasing? Kymera Therapeutics saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 7,180,000 shares, a decrease of 2.6% from the previous total of 7,370,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Kymera Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Kymera Therapeutics: Roivant Sciences Ltd. (12.03%), Revolution Medicines, Inc. (8.89%), BridgeBio Pharma, Inc. (11.68%), Blueprint Medicines Co. (8.76%), Elanco Animal Health Incorporated (5.00%), Legend Biotech Co. (3.67%), TG Therapeutics, Inc. (14.56%), Verona Pharma plc (9.87%), Lantheus Holdings, Inc. (10.28%), Axsome Therapeutics, Inc. (8.53%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Kymera Therapeutics stock? Short selling KYMR is an investing strategy that aims to generate trading profit from Kymera Therapeutics as its price is falling. KYMR shares are trading up $0.04 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Kymera Therapeutics? A short squeeze for Kymera Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of KYMR, which in turn drives the price of the stock up even further. How often is Kymera Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including KYMR, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies Roivant Sciences Short Interest Data Revolution Medicines Short Interest Data BridgeBio Pharma Short Interest Data Blueprint Medicines Short Interest Data Elanco Animal Health Short Interest Data Legend Biotech Short Interest Data TG Therapeutics Short Interest Data Verona Pharma Short Interest Data Lantheus Short Interest Data Axsome Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:KYMR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kymera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kymera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KYMR Stock Free KYMR Stock Alerts